1. Home
  2. CHAC vs NYXH Comparison

CHAC vs NYXH Comparison

Compare CHAC & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHAC
  • NYXH
  • Stock Information
  • Founded
  • CHAC 2025
  • NYXH 2009
  • Country
  • CHAC United States
  • NYXH Belgium
  • Employees
  • CHAC N/A
  • NYXH N/A
  • Industry
  • CHAC
  • NYXH Medical/Dental Instruments
  • Sector
  • CHAC
  • NYXH Health Care
  • Exchange
  • CHAC NYSE
  • NYXH Nasdaq
  • Market Cap
  • CHAC 300.0M
  • NYXH 290.9M
  • IPO Year
  • CHAC 2025
  • NYXH 2021
  • Fundamental
  • Price
  • CHAC $10.10
  • NYXH $7.31
  • Analyst Decision
  • CHAC
  • NYXH Strong Buy
  • Analyst Count
  • CHAC 0
  • NYXH 4
  • Target Price
  • CHAC N/A
  • NYXH $14.50
  • AVG Volume (30 Days)
  • CHAC 457.0
  • NYXH 44.1K
  • Earning Date
  • CHAC 01-01-0001
  • NYXH 08-18-2025
  • Dividend Yield
  • CHAC N/A
  • NYXH N/A
  • EPS Growth
  • CHAC N/A
  • NYXH N/A
  • EPS
  • CHAC N/A
  • NYXH N/A
  • Revenue
  • CHAC N/A
  • NYXH $4,716,818.00
  • Revenue This Year
  • CHAC N/A
  • NYXH $209.22
  • Revenue Next Year
  • CHAC N/A
  • NYXH $219.37
  • P/E Ratio
  • CHAC N/A
  • NYXH N/A
  • Revenue Growth
  • CHAC N/A
  • NYXH N/A
  • 52 Week Low
  • CHAC $9.98
  • NYXH $5.55
  • 52 Week High
  • CHAC $11.28
  • NYXH $11.87
  • Technical
  • Relative Strength Index (RSI)
  • CHAC N/A
  • NYXH 43.37
  • Support Level
  • CHAC N/A
  • NYXH $7.00
  • Resistance Level
  • CHAC N/A
  • NYXH $7.59
  • Average True Range (ATR)
  • CHAC 0.00
  • NYXH 0.33
  • MACD
  • CHAC 0.00
  • NYXH -0.08
  • Stochastic Oscillator
  • CHAC 0.00
  • NYXH 27.89

About CHAC CRANE HBR ACQUISITION CORP

Crane Harbor Acquisition Corp is a blank check company.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: